Ovarian hyperstimulation syndrome

Jump to: navigation, search

For patient information, click here

Ovarian hyperstimulation syndrome
Ovarian-hyperstimulation-004.jpg
Image courtesy of RadsWiki
ICD-10 N98.1
ICD-9 xxx
DiseasesDB 32038
MedlinePlus 007294

WikiDoc Resources for Ovarian hyperstimulation syndrome

Articles

Most recent articles on Ovarian hyperstimulation syndrome

Most cited articles on Ovarian hyperstimulation syndrome

Review articles on Ovarian hyperstimulation syndrome

Articles on Ovarian hyperstimulation syndrome in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ovarian hyperstimulation syndrome

Images of Ovarian hyperstimulation syndrome

Photos of Ovarian hyperstimulation syndrome

Podcasts & MP3s on Ovarian hyperstimulation syndrome

Videos on Ovarian hyperstimulation syndrome

Evidence Based Medicine

Cochrane Collaboration on Ovarian hyperstimulation syndrome

Bandolier on Ovarian hyperstimulation syndrome

TRIP on Ovarian hyperstimulation syndrome

Clinical Trials

Ongoing Trials on Ovarian hyperstimulation syndrome at Clinical Trials.gov

Trial results on Ovarian hyperstimulation syndrome

Clinical Trials on Ovarian hyperstimulation syndrome at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ovarian hyperstimulation syndrome

NICE Guidance on Ovarian hyperstimulation syndrome

NHS PRODIGY Guidance

FDA on Ovarian hyperstimulation syndrome

CDC on Ovarian hyperstimulation syndrome

Books

Books on Ovarian hyperstimulation syndrome

News

Ovarian hyperstimulation syndrome in the news

Be alerted to news on Ovarian hyperstimulation syndrome

News trends on Ovarian hyperstimulation syndrome

Commentary

Blogs on Ovarian hyperstimulation syndrome

Definitions

Definitions of Ovarian hyperstimulation syndrome

Patient Resources / Community

Patient resources on Ovarian hyperstimulation syndrome

Discussion groups on Ovarian hyperstimulation syndrome

Patient Handouts on Ovarian hyperstimulation syndrome

Directions to Hospitals Treating Ovarian hyperstimulation syndrome

Risk calculators and risk factors for Ovarian hyperstimulation syndrome

Healthcare Provider Resources

Symptoms of Ovarian hyperstimulation syndrome

Causes & Risk Factors for Ovarian hyperstimulation syndrome

Diagnostic studies for Ovarian hyperstimulation syndrome

Treatment of Ovarian hyperstimulation syndrome

Continuing Medical Education (CME)

CME Programs on Ovarian hyperstimulation syndrome

International

Ovarian hyperstimulation syndrome en Espanol

Ovarian hyperstimulation syndrome en Francais

Business

Ovarian hyperstimulation syndrome in the Marketplace

Patents on Ovarian hyperstimulation syndrome

Experimental / Informatics

List of terms related to Ovarian hyperstimulation syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ovarian hyperstimulation syndrome (OHSS) is a complication from some forms of fertility medication. Most cases are mild, but a small proportion are severe.

Etiology

Ovarian hyperstimulation syndrome is usually iatrogenic secondary to ovarian stimulant drug therapy for infertility but may occur as a spontaneous event in pregnancy.

Drug Induced

Symptoms

Symptoms are classified into three categories: mild, moderate, and severe.

  • Moderate symptoms include excessive weight gain (weight gain of greater than 2 pounds per day), increased abdominal girth, vomiting, diarrhea, darker urine, reduced urine output, excessive thirst, and dry skin and/or hair.

Classification

In mild forms of OHSS the ovaries are enlarged, in moderate forms there is additional accumulation of ascites with mild abdominal distension, while in severe forms of OHSS there may be hemoconcentration, thrombosis, abdominal pain and distension, oliguria (decreased urine production), pleural effusion, and respiratory distress. Early OHSS develops before pregnancy testing, and late OHSS is seen in early pregnancy.

Complications

OHSS may be complicated with ovarian torsion, ovarian rupture, thrombophlebitis and renal insufficiency. Symptoms generally resolve in 1 to 2 weeks, but will be more severe and persist longer if pregnancy is successful. This is likely due to the role of the corpus luteum in sustaining the pregnancy before the placenta has fully developed. Typically, even in severe OHSS with a developing pregnancy, the duration does not extend beyond the first trimester.

Pathophysiology

OHSS is characterized by the presence of multiple luteinized cysts within the ovaries leading to ovarian enlargement and secondary complications.

As the ovary undergoes a process of extensive luteinization, large amounts of estrogens, progesterone, and local cytokines are released. It has been hypothesized that vascular endothelial growth factor (VEGF) is a key substance that induces OHSS by making local capillaries "leaky", leading to a shift of fluids from the intravascular system to the abdominal and pleural cavity. Thus, while the patient accumulates fluid in the third space, primarily in the form of ascites, she actually becomes hypovolemic and is at risk for respiratory, circulatory, and renal problems. Patients who are pregnant sustain the ovarian luteinization process by the production of hCG.

Epidemiology

Sporadic OHSS is very rare, and may have a genetic component. Clomifene citrate therapy can occasionally lead to OHSS, but the vast majority of cases develop after use of gonadotropin therapy (with administration of FSH), such as Pergonal, and administration of hCG to trigger ovulation, often in conjunction with IVF. The frequency varies and depends on patient factors, management, and methods of surveillance. About 5% of treated patients may encounter moderate to severe OHSS.

Mortality is low, but several fatal cases have been reported.

Diagnostic Findings

  • The imaging findings are similar on ultrasound, CT, and MR imaging.
  • Ovarian enlargement is present caused by distended corpora lutea cysts of varying sizes.
  • Because the enlarged follicles are often peripheral in location, a "wheel spoke" appearance has been described, with stromal ovarian tissue located centrally with surrounding cysts.
  • Familiarity with ovarian hyperstimulation syndrome and the appropriate clinical setting should help avoid the incorrect diagnosis of an ovarian cystic neoplasm.

Images courtesy of RadsWiki

Ovarian-hyperstimulation-001.jpg


Ovarian-hyperstimulation-002.jpg


Ovarian-hyperstimulation-003.jpg


Ovarian-hyperstimulation-004.jpg


Treatment

Physicians can reduce the risk of OHSS by monitoring of FSH therapy to use this medication judiciously, and by withholding hCG medication. Once OHSS develops, reduction in physical activity, closely monitoring fluid and electrolyte balance, and aspiration of accumulated fluid (ascites) from the abdominal/pleural cavity may be necessary, as well as opioids for the pain. If the OHSS develops within an IVF protocol, it can be prudent to postpone transfer of the pre-embryos since establishment of pregnancy can lengthen the recovery time or contribute to a more severe course. Over time, if carefully monitored, the condition will naturally reverse to normal - so treatment is typically supportive, although patient may need to be treated or hospitalized for pain, paracentesis, and/or intravenous hydration.

References

  • Delvigne A, Rozenberg S (2002). "Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review" (PDF). Hum Reprod Update. 8 (6): 559–77. PMID 12498425.
  • Delvigne A, Rozenberg S (2003). "Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS)" (PDF). Hum Reprod Update. 9 (1): 77–96. PMID 12638783.

de:Ovarielles Hyperstimulationssyndrom


Linked-in.jpg